. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

Catalent to Lay Off 350 Workers at Baltimore Gene Therapy Plant 

Podcasts

This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug manufacturing, a multi-billion-dollar Merck KGaA–Skyhawk collaboration to advance RNA therapies in neurology, and how pharmacist-led telehealth is improving diabetes care during emergencies.

Pharma Pulse: Agile Drug Manufacturing Advances, Merck–Skyhawk RNA Deal, and Telehealth Expands Pharmacists’ Role

Videos

In the third part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, describes how AI-driven surveillance and image recognition vastly outpace traditional brand protection methods, enabling pharmaceutical companies to detect and remove millions of counterfeit listings across global online marketplaces and social media in real time.

AI-Powered Tools Transform Fight Against Counterfeit Drugs

The EQUIP-A-Pharma program will combine Battelle’s synthesis platform and Aprecia’s 3D printing technology to produce APIs and finished drugs at the same site, aiming to strengthen US pharma supply resilience and support essential medicines.

Battelle and Aprecia Partner With HHS and DARPA to Advance Agile Drug Manufacturing

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a promising drug combination against resistant influenza strains, and how community pharmacies are strengthening healthcare access in underserved areas.

Pharma Pulse: Wegovy Wins Accelerated Approval, New Flu Combo Emerges, and Community Pharmacies Expand Access

Payer-level reporting should do more than track performance—it must guide strategy, focus resources, and drive measurable brand impact.

Monitoring Payer-Level Performance and Planning

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.

Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs

In the eighth part of this roundtable discussion, supply chain experts emphasize that effective manufacturing strategies depend on product type, market location, and regulatory complexity, requiring a careful balance between outsourcing, internal production, regional distribution, and patient-centric priorities.

Peer Exchange: Pharma Leaders Stress Tailored, Balanced Approach to Long-Term Manufacturing Strategy (Episode 8)

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to support safe use, adherence, and management of related chronic health needs.

Goodpath Partners With GiftHealth to Expand Access to GLP-1 Therapies Through LillyDirect

As over half of Americans now receive prescriptions through Medicare or Medicaid, pharma companies must shift from a commercial-first approach to a statutory-first model, making GTN governance a C-suite priority for long-term brand survival.

News